GISELLE TAMULA: Open Payments
NPI 1932623246 · SANTA MONICA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,146 in 80 payments from 24 companies in 2025. Trend: 2023 $1,758 · 2024 $2,223 · 2025 $2,146
Food & beverage: $2,146
| Company | Payments | Amount |
|---|---|---|
| ACADIA Pharmaceuticals Inc | 13 | $341 |
| UCB, Inc. | 18 | $303 |
| Neurocrine BioSciences, Inc. | 7 | $270 |
| Merz Pharmaceuticals, LLC | 3 | $120 |
| PFIZER INC. | 1 | $120 |
| Biogen, Inc. | 4 | $110 |
| ARGENX US, INC. | 4 | $107 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $104 |
| ABBVIE INC. | 4 | $98 |
| CSL Behring | 2 | $70 |
Products named: NUPLAZID, Zilbrysq, INGREZZA, LEQEMBI, INBRIJA, LORBRENA, VYVGART HYTRULO, ISTURISA.
Industry payments across CA — which companies pay providers there.
